Bendamustine-induced nephrogenic diabetes insipidus – A case report

Author:

Desjardins Audrey1ORCID,Le-Nguyen Viviane1,Turgeon-Mallette Léa1,Vo Chloé1,Boudreault Jean-Samuel2ORCID,Rioux Jean-Philippe3,Feng Xue4,Veilleux Amélie4

Affiliation:

1. Faculty of Pharmacy, Université de Montréal, Montreal, Canada

2. Division of Hematology and Oncology, Department of Medicine, Hôpital du Sacré-Cœur de Montréal, Montreal, Canada

3. Division of Nephrology, Department of Medicine, Hôpital du Sacré-Cœur de Montréal, Montreal, Canada

4. Department of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montreal, Canada

Abstract

Introduction In patients with relapsed or refractory lymphoma, high-dose chemoimmunotherapy with subsequent autologous hematopoietic cell transplantation (HCT) is a standard of care. Bendamustine, an alkylating agent, is used in the BeEAM (bendamustine, etoposide, cytarabine, melphalan) protocol for conditioning therapy before autologous HCT in patients with relapsed or refractory lymphoma who are eligible for transplant. There is no consensus regarding an optimal salvage regimen and the approach varies according to toxicity. Case report We present a case of partial nephrogenic diabetes insipidus after receiving bendamustine, as part of the BeEAM protocol. Management and outcome: The patient was managed with parenteral fluid administration and intranasal desmopressin before the condition resolved on its own. Discussion We summarize published reports of bendamustine-induced diabetes insipidus.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Nephro-oncology: clinical and biochemical aspects of kidney disease and cancer;Acta Biochimica Polonica;2023-05-09

2. Side effects of anti-cancer medications;Side Effects of Drugs Annual;2022

3. Antineoplastics;Reactions Weekly;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3